Frankfurt - Delayed Quote EUR

Collegium Pharmaceutical, Inc. (354.F)

33.00

-0.20

(-0.60%)

As of 8:15 AM GMT+2. Market Open.

Advanced Chart

Loading Chart for 354.F

9/21 12:03 PM

DELL

Previous Close 33.20
Open 33.00
Bid 32.80 x 70000
Ask 33.20 x 70000
Day's Range 33.00 - 33.00
52 Week Range 18.90 - 38.00
Volume 34
Avg. Volume 7
Market Cap (intraday) 1.079B
Beta (5Y Monthly) 1.04
PE Ratio (TTM) 27.27
EPS (TTM) 1.21
Earnings Date May 2, 2024 - May 6, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 26.71

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

www.collegiumpharma.com

197